Clinical Trial to Evaluate the Efficacy and Safety of DWKH

• Status: Completed
• Trial end date: 2022-12-16
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, Double-blind, Parellel, Multicenter, Active-controlled

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daewon Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Male and female aged between 19 and 80.

• Patients whose BSS score is over 5.

Exclusion Criteria:

• Patients allergic to any ingredients of the study drugs.

• Moderate liver disease (ALT or AST > UNLx3).

• Moderate lung disease.

• Uncontrolled HTN.

• Uncontrolled DM.

• Uncontrolled thyroidism.

• Patients who is needed antibiotics during the study period.

• In the case of women, pregnant(Urine-HCG positive) or lactating women.